

Physicochemical Principles of Pharmacy

FIFTH EDITION

Alexander T Florence CBE, DSc, FRSE, FRPharmS
The School of Pharmacy, University of London, UK

David Attwood PhD, DSc, CChem, FRSC
School of Pharmacy and Pharmaceutical Sciences
University of Manchester, UK



Contents

Preface	xv
About the authors	xvii
Introduction	1
1 Solids	7
1.1 Classification of solids	8
1.2 Crystalline solids – structure and properties	8
1.2.1 Crystal structure	8
1.2.2 Crystal form	11
1.2.3 Polymorphism	14
1.2.4 Multicomponent crystals	21
1.3 Amorphous solids	25
1.4 Dissolution of solid drugs	26
1.5 Importance of particle size in the formulation and manufacture of solid dosage forms	28
1.6 Biopharmaceutical importance of particle size	29
1.7 Wetting of powders	31
1.7.1 Contact angle and wettability of solid surfaces	31
1.7.2 Wettability of powders	33
1.8 Sublimation	34
1.9 Solid dispersions	38
1.9.1 Eutectics and drug identification	40
Summary	41
References	42
2 Physicochemical properties of drugs in solution	43
2.1 Concentration units	43
2.1.1 Weight or volume concentration	44
2.1.2 Molarity and molality	44
2.1.3 Milliequivalents	44
2.1.4 Mole fraction	45
2.2 Thermodynamics – a brief introduction	45
2.2.1 Energy	46
2.2.2 Enthalpy	46
2.2.3 Entropy	46
2.2.4 Free energy	48

2.3	Activity and chemical potential	51
2.3.1	Activity and standard states	51
2.3.2	Activity of ionised drugs	51
2.3.3	Solvent activity	53
2.3.4	Chemical potential	55
2.4	Osmotic properties of drug solutions	58
2.4.1	Osmotic pressure	59
2.4.2	Osmolality and osmolarity	59
2.4.3	Clinical relevance of osmotic effects	60
2.4.4	Preparation of isotonic solutions	65
2.5	Ionisation of drugs in solution	66
2.5.1	Clinical relevance of drug ionisation	66
2.5.2	Dissociation of weakly acidic and basic drugs and their salts	67
2.5.3	The effect of pH on the ionisation of weakly acidic or basic drugs and their salts	67
2.5.4	Ionisation of amphoteric drugs	75
2.5.5	Ionisation of polyprotic drugs	76
2.5.6	Microdissociation constants	77
2.5.7	pK_a values of proteins	78
2.5.8	Calculation of the pH of drug solutions	78
2.5.9	Buffer solutions	81
2.6	Diffusion of drugs in solution	85
	Summary	86
	References	87

3 Drug stability **89**

3.1	The chemical decomposition of drugs	90
3.1.1	Hydrolysis	90
3.1.2	Oxidation	91
3.1.3	Isomerisation	93
3.1.4	Photochemical decomposition	95
3.1.5	Polymerisation	97
3.2	Kinetics of chemical decomposition in solution	99
3.2.1	Classifying reactions: the order of reaction	99
3.2.2	Zero-order reactions	100
3.2.3	First-order reactions	100
3.2.4	Second-order reactions	102
3.2.5	Third-order reactions	102
3.2.6	Determination of the order of reaction	102
3.2.7	Complex reactions	105
3.3	Solid dosage forms: kinetics of chemical decomposition	111
3.4	Factors influencing drug stability	112
3.4.1	Liquid dosage forms	112
3.4.2	Semisolid dosage forms	123
3.4.3	Solid dosage forms	124
3.5	Stability testing and prediction of shelf-life	129
3.5.1	Effect of temperature on stability	129

3.5.2	Other environmental factors affecting stability	135
3.5.3	Protocol for stability testing	137
	Summary	138
	References	139
4	The solubility of drugs	141
4.1	Definitions	142
4.1.1	Expressions of solubility	142
4.2	Factors influencing solubility	142
4.2.1	Structural features and aqueous solubility	143
4.2.2	Hydration and solvation	148
4.2.3	The effect of simple additives on solubility	151
4.2.4	The effect of pH on the solubility of ionisable drugs	152
4.3	Measurement of solubility	159
4.4	The solubility parameter	161
4.4.1	Solubility parameters and biological processes	161
4.5	Solubility in mixed solvents	162
4.6	Cyclodextrins as solubilising agents	163
4.7	Solubility problems in formulation	165
4.7.1	Mixtures of acidic and basic compounds	165
4.7.2	Choice of drug salt to optimise solubility	165
4.7.3	Drug solubility and biological activity	167
4.8	Partitioning	170
4.8.1	The partition coefficient	170
4.8.2	Free energies of transfer	171
4.8.3	Octanol as a nonaqueous phase	171
4.9	Biological activity and partition coefficients: thermodynamic activity and Ferguson's principle	171
4.10	Using log <i>P</i>	174
4.10.1	The relationship between lipophilicity and behaviour of tetracyclines	175
4.10.2	Sorption	177
4.10.3	A chromatographic model for the biophase	178
4.10.4	Calculating log <i>P</i> from molecular structures	178
4.10.5	Drug distribution into human milk	179
	Summary	183
	References	183
5	Surfactants	185
5.1	Amphipathic compounds	186
5.2	Surface and interfacial properties of surfactants	187
5.2.1	Effects of amphiphiles on surface and interfacial tension	187
5.2.2	Change of surface tension with surfactant concentration – the critical micelle concentration	188
5.2.3	Gibbs adsorption equation	188
5.2.4	The influence of the surfactant structure on surface activity	192
5.2.5	Surface activity of drugs	192
5.2.6	Insoluble monolayers	194

5.2.7	Pharmaceutical applications of surface film studies	200
5.2.8	Adsorption at the solid-liquid interface	203
5.3	Micellisation	212
5.3.1	Water structure and hydrophobic bonding	213
5.3.2	Theories of micelle formation	214
5.3.3	Micellar structure	215
5.3.4	Factors affecting the critical micelle concentration and micellar size	218
5.4	Liquid crystals and surfactant vesicles	221
5.4.1	Liquid crystals	221
5.4.2	Liposomes, niosomes and surfactant vesicles	224
5.5	Properties of some commonly used surfactants	227
5.5.1	Anionic surfactants	227
5.5.2	Cationic surfactants	227
5.5.3	Nonionic surfactants	228
5.6	Solubilisation	232
5.6.1	Determination of maximum additive concentration	232
5.6.2	Location of the solubilisate	233
5.6.3	Factors affecting solubilisation	233
5.6.4	Pharmaceutical applications of solubilisation	237
	Summary	238
	References	239
6	Emulsions, suspensions and other disperse systems	241
6.1	Colloids and their classification	242
6.2	Colloid stability	243
6.2.1	Forces of interaction between colloidal particles	243
6.2.2	Repulsion between surfaces with macromolecular stabilisers	247
6.3	Emulsions	249
6.3.1	Stability of o/w and w/o emulsions	250
6.3.2	HLB system	251
6.3.3	Multiple emulsions	253
6.3.4	Microemulsions	255
6.3.5	Structured (semisolid) emulsions	258
6.3.6	Biopharmaceutical aspects of emulsions	259
6.3.7	Preservative availability in emulsified systems	260
6.3.8	Mass transport in oil-in-water emulsions	261
6.3.9	Intravenous fat emulsions	261
6.3.10	Emulsion rheology	262
6.4	Suspensions	265
6.4.1	Stability of suspensions	265
6.4.2	Extemporaneous suspensions	270
6.4.3	Suspension rheology	270
6.4.4	Nonaqueous suspensions	271
6.4.5	Electrostatics in aerosols	272
6.4.6	Adhesion of suspension particles to containers	272
6.4.7	Powder processing	273

6.5	Miscellaneous colloidal systems	274
6.6	Applications of colloid stability theory to other systems	274
6.6.1	Cell-cell interactions	276
6.6.2	Adsorption of microbial cells to surfaces	276
6.6.3	Blood as a colloidal system	277
6.7	Foams	277
	Summary	279
	References	280
7	Polymers and macromolecules	281
7.1	Pharmaceutical polymers	282
7.1.1	Definitions	282
7.1.2	Polydispersity	284
7.1.3	Polymer mixtures or blends	284
7.1.4	Polymer solubility	284
7.2	Water-soluble polymers	288
7.3	General properties of polymer solutions	289
7.3.1	Viscosity of polymer solutions	289
7.3.2	Gel formation	292
7.3.3	Syneresis	293
7.3.4	Polymer complexes	294
7.3.5	Binding of ions to macromolecules	295
7.3.6	Interaction of polymers with solvents including water	295
7.3.7	Adsorption of macromolecules	298
7.4	Water-soluble polymers used in pharmacy and medicine	299
7.4.1	Carboxypolymethylene (Carbomer, Carbopol)	300
7.4.2	Cellulose derivatives	300
7.4.3	Natural gums and mucilages	302
7.4.4	Chitosan	303
7.4.5	Dextran	304
7.4.6	Polyvinylpyrrolidone	305
7.4.7	Polyoxyethylene glycols (Macrogols)	306
7.4.8	Bioadhesivity of water-soluble polymers	307
7.4.9	Polymers as wound dressings	308
7.4.10	Polymer crystallinity	308
7.5	Water-insoluble polymers and polymer membranes	309
7.5.1	Permeability of polymers	309
7.5.2	Ion-exchange resins	312
7.5.3	Silicone oligomers and polymers	314
7.6	Some applications of polymeric systems in drug delivery	316
7.6.1	Film coating	316
7.6.2	Matrices	317
7.6.3	Microcapsules and microspheres	319
7.6.4	Rate-limiting membranes and devices	323
7.6.5	Eroding systems	323
7.6.6	Osmotic pumps	324
7.6.7	Transdermal delivery systems	325

Summary	330
References	330
Further reading	330
8 Pharmaceutical nanotechnology	331
Introduction	332
8.1 Particle size	334
8.2 Physicochemical characterisation of nanosystems	334
8.3 Nanoparticles in pharmacy	334
8.3.1 Nanoparticles as drug carriers	335
8.3.2 Application of nanoparticles in drug delivery	336
8.4 Nanoparticle manufacturing methods	337
8.4.1 Solvent displacement	337
8.4.2 Salting-out	338
8.4.3 Emulsion-diffusion	338
8.4.4 Emulsion-solvent evaporation	338
8.4.5 Supercritical fluid technologies	338
8.4.6 Coacervation and complexation techniques	339
8.4.7 <i>In situ</i> polymerisation	339
8.5 Nanocrystal formation	341
8.6 Drug targeting with nanoparticles – particle flow	342
8.7 Aggregation	342
8.8 PEGylated nanoparticles	342
8.9 Nanoparticle diffusion	344
8.10 Regulatory challenges: characterisation	344
Summary	344
References	
9 Drug absorption and the oral route	347
9.1 Biological membranes and drug transport	348
9.1.1 Lipophilicity and absorption	350
9.1.2 Permeability and the pH-partition hypothesis	351
9.1.3 Problems with the quantitative application of the pH-partition hypothesis	352
9.2 The oral route and oral absorption	357
9.2.1 Drug absorption from the gastrointestinal tract	357
9.2.2 Structure of the gastrointestinal tract	357
9.2.3 Bile salts and fat absorption pathways	360
9.2.4 Gastric emptying, motility and volume of contents	360
9.3 Oral dosage forms	362
9.3.1 The Biopharmaceutical Classification System (BCS)	362
9.4 Buccal and sublingual absorption	364
9.4.1 Mechanisms of absorption	364
Summary	365
References	367

10	Parenteral routes of drug administration	369
10.1	Intravenous and intra-arterial administration	370
10.2	Intramuscular and subcutaneous injection	371
10.2.1	The importance of site of injection	373
10.2.2	Vehicles	373
10.2.3	Blood flow in muscles	374
10.2.4	Formulation effects	374
10.2.5	The case of insulin	375
10.3	Transdermal delivery	378
10.3.1	Routes of skin penetration	379
10.3.2	Influence of the drug	380
10.3.3	Influence of the vehicle	382
10.3.4	Dilution of topical steroid preparations	385
10.3.5	Transdermal medication: patches and devices	385
10.3.6	Ultrasound and transdermal penetration	386
10.3.7	Jet injectors	387
10.3.8	Topical treatment of the nails: trans-ungual therapy	387
10.4	Medication of the eye and the eye as a route for systemic delivery	389
10.4.1	The eye	389
10.4.2	Absorption of drugs applied to the eye	390
10.4.3	Influence of formulation	391
10.4.4	Systemic effects from eye-drops	395
10.5	The ear (the aural route)	397
10.6	Absorption from the vagina	397
10.6.1	Delivery systems	398
10.7	Inhalation therapy	398
10.7.1	Physical factors affecting deposition of aerosols	399
10.7.2	Experimental observations	402
10.8	The nasal route	407
10.9	Rectal absorption of drugs	409
10.10	Intrathecal drug administration	413
	Summary	413
	References	414
	Further reading	414
11	Physicochemical drug interactions and incompatibilities	415
11.1	pH effects <i>in vitro</i> and <i>in vivo</i>	416
11.1.1	<i>In vitro</i> pH effects	416
11.1.2	<i>In vivo</i> pH effects	418
11.2	Dilution of mixed solvent systems	422
11.3	Cation-anion interactions	423
11.4	Polyions and drug solutions	426
11.5	Chelation	427
11.6	Other complexes	431
11.6.1	Interaction of drugs with cyclodextrins	432
11.6.2	Ion-exchange interactions	433

11.7	Adsorption of drugs	435
11.7.1	Protein and peptide adsorption	436
11.7.2	Protein aggregation and interactions	437
11.8	Drug interactions with plastics	438
11.9	Protein binding	439
11.9.1	Thermodynamics of protein binding	441
11.9.2	Lipophilicity and protein binding	441
11.9.3	Penetration of specialised sites	445
	Summary	445
	Appendix: Drug interactions based on physical mechanisms	446
	A: Interactions affecting absorption of drugs	446
	B: Interactions involving protein binding	447
	References	449

12 Peptides, proteins and other biopharmaceuticals **451**

12.1	Structure and solution properties of peptides and proteins	452
12.1.1	Structure of peptides and proteins	452
12.1.2	Hydrophobicity of peptides and proteins	453
12.1.3	Solubility of peptides and proteins	453
12.2	The stability of proteins and peptides	459
12.2.1	Physical instability	460
12.2.2	Formulation and protein stabilisation	462
12.2.3	Chemical instability	464
12.3	Protein formulation and delivery	465
12.3.1	Protein and peptide transport	465
12.3.2	Lyophilised proteins	466
12.3.3	Water adsorption	467
12.3.4	PEGylation of peptides and proteins	467
12.3.5	Routes of delivery	469
12.4	A therapeutic protein and a peptide	469
12.4.1	Insulin	469
12.4.2	Calcitonin	471
12.5	DNA and oligonucleotides	471
12.5.1	DNA	471
12.5.2	Oligonucleotides	473
12.6	Therapeutic monoclonal antibodies	474
	Summary	475
	References	476

13 Physical assessment of dosage forms **479**

13.1	Dissolution testing of solid oral dosage forms	480
13.1.1	Pharmacopoeial and compendial dissolution tests	480
13.1.2	Flow-through systems	482
13.2	<i>In vitro</i> – <i>in vivo</i> correlations	482

13.3	Evaluation of suppositories and topical preparations	482
13.3.1	Suppository formulations	482
13.3.2	<i>In vitro</i> release from topical products and transdermal systems	483
13.4	Rheological characteristics of products	486
13.5	Adhesivity of dosage forms	486
13.6	Gastro-retentive systems: buoyancy tests	490
13.7	Evaluation of aerosols	490
	Summary	493
	References	493
Index		495